Menée par la Pre Catia Marzolini du Service de Pharmacologie Clinique, une étude récemment publiée dans la revue Clinical Infectious Diseases a évalué…
In our division, clinicians and scientists work together to dissect the mechanisms through which the immune system protects us from invading pathogens/antigens and why it sometimes fails to do so or overreacts.
Research performed by the Division of Immunology and Allergy includes both fundamental as well as applied clinical research. Senior scientists, post docs, PhD students, research assistants, doctors and biomedical laboratory scientists work closely together on research projects. Researchers strive to understand how the immune system works at the cellular and molecular levels to help the development of new therapies for diseases such as AIDS, tuberculosis and other pathogens induced disease. The Division of Immunology and Allergy also focuses on several different areas of basic cellular immunobiology relevant for the understanding of host-pathogens interactions and vaccine design such as functional aspects of T and B-lymphocytes, antiviral and mucosal immunity, generation of immunological tolerance in allergies and transplant patients.
In particular, we are actively pursuing the following research areas:
Researchers can rely on state of the art Clinical Immune-Monitoring Platform enabling them to develop new diagnostic tools as well as new vaccine candidates.
The division has a strong expertise in vaccine evaluation, with a specialized clinical investigation unit: the Vaccine and Immunotherapy Center (VIC) and an immune-monitoring laboratory. The VIC conducts phase I, II and III clinical trials in the field of vaccinology and immunology.
Through partnership and collaboration with other academic laboratories as well as the industry, the division bridges the gap between fundamental and clinical research to translate basic immunology into medicine.
Menée par la Pre Catia Marzolini du Service de Pharmacologie Clinique, une étude récemment publiée dans la revue Clinical Infectious Diseases a évalué…
Une équipe romande, sous l'égide du Swiss Cancer Center Léman (SCCL), a découvert comment améliorer le pouvoir antitumoral des cellules CAR-T, des…
Le Pr François Girardin a été nommé chef du Service ad interim de la pharmacologie clinique du CHUV. Il succède au Pr Thierry Buclin, qui a pris sa…
En 2022, la Fondation CHUV a versé près de CHF 4.8 millions au CHUV ! Hôpital des enfants, recherche contre le glioblastome, matériel médical pour…